CalciMedica Launches Phase 2 KOURAGE Trial of Auxora in Acute Kidney Injury with Respiratory Failure

Reuters

2025/11/12

CalciMedica Launches Phase 2 KOURAGE Trial of Auxora in Acute Kidney Injury with Respiratory Failure

CalciMedica Inc. has announced ongoing enrollment in its Phase 2 KOURAGE trial, evaluating Auxora™ in patients with Stage 2 or Stage 3 acute kidney injury (AKI) with respiratory failure. The company plans to enroll 150 patients, with data expected in the first half of 2026. Additionally, CalciMedica reported positive discussions with the U.S. Food and Drug Administration (FDA) regarding the design of a pivotal trial in acute pancreatitis $(AP)$, with final trial design anticipated in the first half of 2026. In November 2025, preclinical results on Auxora were presented at the American Society of Nephrology (ASN) Kidney Week, showing improved kidney function and reduced renal injury in a rat model of AKI. CalciMedica has also entered a collaboration with Telperian to utilize AI insights in support of its AP pivotal trial design.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CalciMedica Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA21933) on November 12, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2582373023"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2582373023\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2582373023?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-12 20:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2582373023","market":"us","top_or_hot":-1,"title":"CalciMedica Launches Phase 2 KOURAGE Trial of Auxora in Acute Kidney Injury with Respiratory Failure","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      CalciMedica Launches Phase 2 KOURAGE Trial of Auxora in Acute Kidney Injury with Respiratory Failure\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        CalciMedica Inc. has announced ongoing enrollment in its Phase 2 KOURAGE trial, evaluating Auxora™ in patients with Stage 2 or Stage 3 acute kidney injury (AKI) with respiratory failure. The company plans to enroll 150 patients, with data expected in the first half of 2026. Additionally, CalciMedica reported positive discussions with the U.S. Food and Drug Administration (FDA) regarding the design of a pivotal trial in acute pancreatitis <a href=\"https://laohu8.com/S/AP\">$(AP)$</a>, with final trial design anticipated in the first half of 2026. In November 2025, preclinical results on Auxora were presented at the American Society of Nephrology (ASN) Kidney Week, showing improved kidney function and reduced renal injury in a rat model of AKI. CalciMedica has also entered a collaboration with Telperian to utilize AI insights in support of its AP pivotal trial design.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CalciMedica Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA21933) on November 12, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CalciMedica Launches Phase 2 KOURAGE Trial of Auxora in Acute Kidney Injury with Respiratory Failure</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCalciMedica Launches Phase 2 KOURAGE Trial of Auxora in Acute Kidney Injury with Respiratory Failure\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-12 20:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      CalciMedica Launches Phase 2 KOURAGE Trial of Auxora in Acute Kidney Injury with Respiratory Failure\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        CalciMedica Inc. has announced ongoing enrollment in its Phase 2 KOURAGE trial, evaluating Auxora™ in patients with Stage 2 or Stage 3 acute kidney injury (AKI) with respiratory failure. The company plans to enroll 150 patients, with data expected in the first half of 2026. Additionally, CalciMedica reported positive discussions with the U.S. Food and Drug Administration (FDA) regarding the design of a pivotal trial in acute pancreatitis <a href=\"https://laohu8.com/S/AP\">$(AP)$</a>, with final trial design anticipated in the first half of 2026. In November 2025, preclinical results on Auxora were presented at the American Society of Nephrology (ASN) Kidney Week, showing improved kidney function and reduced renal injury in a rat model of AKI. CalciMedica has also entered a collaboration with Telperian to utilize AI insights in support of its AP pivotal trial design.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CalciMedica Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA21933) on November 12, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CALC","symbol_name":"CALCIMEDICA","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nNDL2Gz9x9:1","article_id":"2582373023","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2582373023","pubTimestamp":1762948973,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"CalciMedica Inc. has announced ongoing enrollment in its Phase 2 KOURAGE trial, evaluating Auxora in patients with Stage 2 or Stage 3 acute kidney injury  with respiratory failure. The company plans to enroll 150 patients, with data expected in the first half of 2026. Additionally, CalciMedica reported positive discussions with the U.S. Food and Drug Administration  regarding the design of a pivotal trial in acute pancreatitis , with final trial design anticipated in the first half of 2026. In November 2025, preclinical results on Auxora were presented at the American Society of Nephrology  Kidney Week, showing improved kidney function and reduced renal injury in a rat model of AKI. CalciMedica has also entered a collaboration with Telperian to utilize AI insights in support of its AP pivotal trial design.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-genera","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CALC":"CALCIMEDICA","BK4007":"制药"},"translate_title":"CalciMedica启动Auxora治疗急性肾损伤伴呼吸衰竭的2期KOURAGE试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CALC":0.9},"content_text":"CalciMedica Launches Phase 2 KOURAGE Trial of Auxora in Acute Kidney Injury with Respiratory Failure\n    \n\n        CalciMedica Inc. has announced ongoing enrollment in its Phase 2 KOURAGE trial, evaluating Auxora™ in patients with Stage 2 or Stage 3 acute kidney injury (AKI) with respiratory failure. The company plans to enroll 150 patients, with data expected in the first half of 2026. Additionally, CalciMedica reported positive discussions with the U.S. Food and Drug Administration (FDA) regarding the design of a pivotal trial in acute pancreatitis $(AP)$, with final trial design anticipated in the first half of 2026. In November 2025, preclinical results on Auxora were presented at the American Society of Nephrology (ASN) Kidney Week, showing improved kidney function and reduced renal injury in a rat model of AKI. CalciMedica has also entered a collaboration with Telperian to utilize AI insights in support of its AP pivotal trial design.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CalciMedica Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA21933) on November 12, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}